Lymphoma & Plasma Cell Disorders
The JCSO Interview
Big survival gains were reported in patients with relapsed/refractory DLBCL treated with polatuzumab vedotin, bendamustine, and rituximab.
From the Journals
The good practice paper includes new information on pathology and use of PET/CT scanning in staging of disease.
The drug is indicated for patients with CLL or SLL, with or without 17p deletion, who have had at least one prior therapy.